Company Overview
Company Type: Public Company
Website: spectraldx.com
Number of Employees: 32
Ticker: EDT (TSX)
Year Founded: 1991


Business Description
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
1.7
Market Capitalization
90.5
TEV/Total Revenue
54.2x
EBITDA
(9.2)
Total Enterprise Value
94.5
TEV/EBITDA
NM
EBIT
(9.3)
Cash & ST Invst.
2.5
P/Diluted EPS Before Extra
NM
Net Income
(11.3)
Total Debt
6.5
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
6.3
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.01)
(0.01)
(0.03)
(0.03)
(0.03)
Revenue (mm)
0.30
0.70
2.00
3.70
2.85
EBITDA (mm)
-
-
(5.10)
(5.80)
(5.45)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
47.26x
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Buy (1.00)
Target Price
1.60
Potential Upside
392.31%


Key Professionals
Name
Title
Seto, Christopher 
CEO & Director
McInnis, Blair 
Chief Financial Officer
Kellum, John A.
Chief Medical Officer

Key Board Members
Name
Title
Bihl, Anthony P.
Independent Chairman of the Board
Seto, Christopher 
CEO & Director
Stevens, William 
Independent Director
D'Alvise, Janelle 
Independent Director
Feigal, David W.
Director
Hayakawa, Jun 
Independent Director
Walker, Paul M.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
135 The West Mall Unit 2 | Toronto, ON | M9C 1C2 | Canada
Phone: 416-626-3233    Fax: 866-332-2699

Current and Pending Investors
Birch Hill Equity Partners Management Inc., GrowthWorks Ltd., Lumira Ventures, Paradigm Capital Inc. (Pending), Toray Industries, Inc. (TSE:3402)

Prior Investors
Canadian Medical Discoveries Fund II, Canadian Medical Discoveries Fund Inc., GrowthWorks Canadian Fund Ltd., L.P., Medwell Capital Corp., Medwell Capital Corp., Asset Management Arm, Pinetree Capital Ltd. (TSX:PNP)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.33
Market Cap (mm)
90.5
Open
 0.33
Shares Out. (mm)
278.6
Previous Close
 0.33
Float %
68.0%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(1.5)%
Dividend Yield %
-
Day High/Low
 0.33/ 0.33
Diluted EPS Excl. Extra Items
(0.03)
52 wk High/Low
 0.42/ 0.23
P/Diluted EPS Before Extra
NM
Volume (mm)
0.01
Avg 3M Dly Vlm (mm)
0.07
Beta 5Y
0.86


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:EDT - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
IDx Inc.
IDx Inc. was acquired by Spectral Diagnostics Inc. IDx Inc. is a research and development company that develops diagnostic assays for infectious diseases. The company is based in Canada.

United States and Canada
Pharmaceuticals
-
-
-
Sepsis, Inc.
Sepsis Inc. develops diagnosis devices for infectious diseases. The company offers Endotoxin Activity Assay (EAA), which is a device used for determination of endotoxin activity in human blood samples, to rule out Gram-negative infection. Sepsis is based in Toronto, Canada. As of 06/18/2001, Sepsis Inc. is a subsidiary of Spectral Diagnostics Inc.

United States and Canada
Health Care Equipment
-
-
-
Dialco Medical Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-10-2023
Sep-07-2023
Private Placement
Target
Spectral Medical Inc. (TSX:EDT)


4.55
Oct-05-2022
Nov-02-2022
Private Placement
Target
Spectral Medical Inc. (TSX:EDT)


5.01
Oct-5-2022
Nov-2-2022
Public Offering
Target
Spectral Medical Inc. (TSX:EDT)


2.95
Jul-20-2021
Jul-27-2021
Public Offering
Target
Spectral Medical Inc. (TSX:EDT)


7.96
Jun-26-2020
-
Shelf Registration
Target
Spectral Medical Inc. (TSX:EDT)


38.84
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-03-2023
Product-Related Announcements
Spectral Medical Inc. Provides an Update on the Progress of Its Tigris Trial Including Patient Enrollment
Oct-02-2023
Executive/Board Changes - Other
Spectral Medical Inc. Announces Stepping Down of John Nosenzo from It's Board of Directors Due to Health Reasons, Effective October 1, 2023
Sep-07-2023
Private Placements
Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding
Aug-10-2023
Private Placements
Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding
Jul-25-2023
Product-Related Announcements
Spectral Medical Inc. Announces Tigris Clinical Trial Update

Competitors
Baxter International Inc. (NYSE:BAX), Cytosorbents Corporation (NasdaqCM:CTSO), Eli Lilly and Company (NYSE:LLY), Jafron Biomedical Co.,Ltd. (SZSE:300529)

M&A Advisors
Stikeman Elliott LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Stikeman Elliott LLP
Private Placement Advisors
Cormark Securities (USA) Limited, Desjardins Securities Inc., Loewen Ondaatje McCutcheon Limited, Investment Banking Arm, MGI Securities Inc., Paradigm Capital Inc., RF Securities Clearing LP
Public Offering Advisors
PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Canada, Stikeman Elliott LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:13 AM
EDT
Spectral Medical Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:11 AM
EDT
ValuEngine - Toronto Quantitative Stock Report for EDT
Reports
9
MarketLine

Sep 30, 2023 06:01 AM
EDT
Spectral Medical Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
115
MarketLine

Sep 20, 2023 06:01 AM
EDT
Spectral Medical Inc.
Reports
37
GlobalData

Sep 12, 2023 03:36 AM
EDT
Spectral Medical Inc (EDT.TSE) - Financial Analysis Review
Reports
227
S&P Global Compustat

Sep 07, 2023 02:54 AM
EDT
Spectral Medical Inc 2023_09_07
Reports
14
ValuEngine, Inc.

Sep 01, 2023 02:48 AM
EDT
ValuEngine Rating and Forecast Report for EDTXF
Reports
11
GlobalData

Aug 29, 2023 01:47 AM
EDT
Spectral Medical Inc (EDTXF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
48
GlobalData

Aug 23, 2023 06:35 AM
EDT
Spectral Medical Inc (EDTXF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
53
S&P Global Compustat

Jul 06, 2023 02:37 AM
EDT
Spectral Medical Inc 2023_07_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Toray Industries, Inc.

45,630,105

16.38

14.8

May-05-2023


Birch Hill Equity Partners Management Inc.

36,210,017

13.00

11.8

May-05-2023


Lubexx Enterprises Ltd.

2,125,078

0.76

0.7

Dec-31-2022


Walker F.R.C.S., M.D., Ph.D., Paul M.

1,878,855

0.67

0.6

Oct-02-2023


Bihl III, Anthony P.

1,561,030

0.56

0.5

Oct-02-2023


Stevens, William 

771,795

0.28

0.3

Oct-02-2023


Seto, Christopher 

599,870

0.22

0.2

Jun-30-2023


Foster B.Sc., CCRC, RN, Debra-Anne M.

181,249

0.07

0.1

Aug-22-2022


Purpose Investments Inc.

136,377

0.05

0.0

Apr-30-2023


Kellum M.D., John A.

108,824

0.04

0.0

Jun-30-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Funk, James 
0
(4,578,504)
Stevens, William 
771,795
(123,637)
Benedetti and Gucer, Inc.
0
(22,200)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
DIMI Machine (Future), Endotoxin Activity Assay, PMX Cartridge (Future), PMX Therapeutic Device, Reagents, Spectral Apheresis Machine, Tigris (Future), Toraymyxin


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Oct-03-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
30 KB
Oct-02-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
28 KB
Sep-13-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
33 KB
Sep-08-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
Documents Affecting the Rights of Security Holders
141 KB
Sep-08-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
34 KB
Sep-07-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
29 KB
Sep-07-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
27 KB
Sep-07-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
Material Change Report
167 KB
Aug-22-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
25 KB
Aug-16-2023
Spectral Medical Inc. (TSX:EDT)
SEDAR
News Releases
33 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Walker F.R.C.S., M.D., Ph.D., Paul M. (Director)
Dec-08-2022
Common Shares
14,717
-
Derivative Exercise and Retained Stock
0.79
Multiple
Bihl III, Anthony P. (Independent Chairman of the Board)
Nov-02-2022
Common Shares
512,500
204,805
Open Market Acquisition
48.88
Multiple
Kellum M.D., John A. (Chief Medical Officer)
Nov-02-2022
Common Shares
50,000
19,981
Open Market Acquisition
85.00
Multiple
Stevens, William  (Independent Director)
Nov-02-2022
Common Shares
250,000
99,905
Open Market Acquisition
47.91
Multiple
Seto, Christopher  (CEO & Director)
Nov-02-2022
Common Shares
125,000
49,952
Open Market Acquisition
26.32
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bihl, Anthony P.
Independent Chairman of the Board
416-626-3233 
866-332-2699

Seto, Christopher 
CEO & Director
416-626-3233x2004
866-332-2699
cseto@spectraldx.com
Stevens, William 
Independent Director
416-626-3233 
866-332-2699

D'Alvise, Janelle 
Independent Director
(450) 686-4555
(450) 686-2505

Feigal, David W.
Director
416-626-3233 
866-332-2699

Hayakawa, Jun 
Independent Director
416-626-3233 
866-332-2699

Walker, Paul M.
Director
416-626-3233x2100
866-332-2699
pwalker@spectraldx.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Seto, Christopher 
CEO & Director
416-626-3233x2004
866-332-2699
cseto@spectraldx.com
McInnis, Blair 
Chief Financial Officer
416-626-3233 
866-332-2699
blair.mcinnis@smtc.com
Kellum, John A.
Chief Medical Officer
416-626-3233 
866-332-2699

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
